Replies to post #205487 on Biotech Values

[DewDiligence]

AZN/(ADXS)—FDA lifts partial hold on Durvalumab H&N trials:

http://www.dailymail.co.uk/wires/reuters/article-3959940/AstraZeneca-cleared-resume-enrolment-cancer-drug-trials.html

U.S. officials have given a green light for two clinical trials testing AstraZeneca's immunotherapy drug durvalumab in head and neck cancer to resume recruiting patients, lifting a hold imposed following cases of bleeding.

One of the late-stage Phase III trials had already re-opened for new patient enrolment and the second was expected to resume recruitment shortly, the British drugmaker said on Tuesday.

This is a boost for ADXS, who is collaborating with AZN on a phase-1/2 trial of AXAL + Durvalumab in patients with H&N or cervical cancer (see fifth bullet item in #msg-119786171).